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Simple Summary: The introduction of immunotherapy has had a significant impact on the cancer
treatment landscape, with unprecedented survival outcomes in some tumor types. However, clinical
development of immune-oncology (IO) agents presents both opportunities and challenges, and not
all patients benefit to the same extent. Many factors influence trial designs and could potentially
threaten the success of promising IO drugs: 1. Most IO trials still rely on response evaluation criteria
based on image assessment only, while new approaches including biomarkers tracking response
should be incorporated. 2. Surrogate endpoints for efficacy are still inferred from classical anticancer
drugs that have not been specifically validated for IO trials. 3. There is a need for biomarker-driven
clinical studies in order to select appropriated patients. 4. Long-term toxicity monitoring is needed,
and dosage calculation should not rely on dose-dependent toxicities. 5. Optimizing the design of
new IO agents with collaborative approaches assessing multiple drugs on a biomarker-based basis
is needed.
Abstract: The rapidly evolving landscape of immuno-oncology (IO) is redefining the treatment of
a number of cancer types. IO treatments are becoming increasingly complex, with different types
of drugs emerging beyond checkpoint inhibitors. However, many of the new drugs either do not
progress from phase I-II clinical trials or even fail in late-phase trials. We have identified at least
five areas in the development of promising IO treatments that should be redefined for more efficient
designs and accelerated approvals. Here we review those critical aspects of IO drug development
that could be optimized for more successful outcome rates in all cancer types. It is important to
focus our efforts on the mechanisms of action, types of response and adverse events of these novel
agents. The use of appropriate clinical trial designs with robust biomarkers of response and surrogate
endpoints will undoubtedly facilitate the development and subsequent approval of these drugs.
Further research is also needed to establish biomarker-driven strategies to select which patients may
benefit from immunotherapy and identify potential mechanisms of resistance.
Keywords: immuno-oncology; cancer; trial design; endpoints; biomarkers
1. Introduction
Immuno-oncology (IO) is redefining the cancer treatment landscape and the way
that some solid tumors are treated. Almost 5000 new agents from six different main
classes of immunotherapies have been in the drug development pipeline within 2020,
including adoptive cell therapy, cancer vaccines, T cell-targeted immunomodulators, other
immunomodulators, oncolytic viruses and antibody-based targeted therapies [1]. Overall,
IO consists of a wide range of drugs with different mechanisms of action that ultimately lead
to the enhancement of immunity against tumor cells. The immune checkpoint inhibitors,
which reactivate T-lymphocyte mediated immune response against tumor cells, have been
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the most successful type of IO developed since the beginning of the “IO era”. Their use is
now a standard of care across several solid tumors, including melanoma, non-small cell
lung cancer (NSCLC), gastric cancer, head and neck squamous cell carcinoma, renal cancer,
bladder cancer, cervical cancer and triple-negative breast cancer (BC) among others [2–6].
1.1. Which Are the Current Challenges with IO?
A substantial number of IO therapies do not progress from phase I-II trials, and
some fail in late-trial stages [7]. First, clinical trials testing novel IO drugs still rely on
biomarkers and endpoints that are validated for conventional treatments such as cytotoxic
agents, although their mechanisms of action are different [8]. Second, the adaptative
immune response induced by immunotherapeutic agents is often sustained in time, as
well as the inflammatory and autoimmune-related adverse events. Those long-term effects
make the evaluation of clinical benefits and toxicities extremely difficult [9]. A wide
range of exclusive toxicities to IO agents, mainly characterized by significant latency,
has been underestimated by many clinical trials as they are only evident in long-term
follow-up or pharmacovigilance studies [10–12]. In addition, the calculation of the IO drug
doses still relies on dose-limiting toxicities seen in the first cycles of classical anticancer
treatments, which seems inadequate for IO treatment. Furthermore, the differences in
the intrinsic biology between IO agents and conventional therapies further complicate
their comparisons. Finally, some particular pathways in IO are overcrowded with similar
drugs within the same therapeutical setting but led by different pharmaceutical companies.
However, these resources could be better relocated to the development of new biomarkers
to select the best in class and to test mechanistically different drugs.
BC, for example, is much in need of a paradigm shift of better IO drug development [13].
This cancer type belongs to a group of widely considered “cold tumors”, characterized
by low mutation and neoantigen burden and low counts of tumor-infiltrating cells (TILs).
Although the number of clinical trials assessing the use of immunotherapy in BC is increas-
ing, to date, the approval of its use is only for a selected subset of advanced triple-negative
(TN) BC patients with >1% of programmed death ligand 1 (PD-L1) expression by immuno-
histochemistry (IHC) [6,14]. Overall, the main problem in the development of IO agents in
this type of cancer has been the lack of biomarker-guided patient selection for trials and
the reliance on a reduced number of “classic” biomarkers such as PD-L1. In particular,
PD-L1 remains at least insufficient to fully explain the therapeutic success and durable
clinical benefit seen in some patients with PD-L1 non-expressing tumors, especially when
treated with other IO agents beyond checkpoint inhibitors [15–19]. However, new genomic
alterations such as those in DNA damage response or specific mutated gene pathways
have shown promising results as immunomarkers in some translational studies, and their
validation in clinical trials should be encouraged [20]. In addition, the main focus of IO
development in BC has been put in TNBC due to its general enrichment of TILs and the
lack of effective therapies other than chemotherapy. Although the use of IO agents in
other subsets of BC, such as luminal B tumors or pretreated HER2-positive BC, has also
been explored, there is still much controversy on its use in those settings [21–23]. It is still
unclear whether a better design based on a more accurate selection and less pretreated
patients would have led to positive results. The other main issue is the lack of assessment
of IO agents’ combinations, which is now believed to be an alternative strategy to achieve
immune response enhancement in “colder tumors”. Especially in BC, in which many
different pathways, such as estrogen receptor signaling, seem to have major implications
for the tumor immune scape, and further combinations of different IO treatments with
classical anticancer therapies could potentially help to overcome them [24,25].
1.2. How Can We Do Better?
Despite the great improvement in the field of IO in the past years, most new agents
still offer a modest rate of objective responses and poor long-term outcomes compared to
conventional treatments. In addition, immune-mediated serious adverse events remain a
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potential issue [26]. In order to optimize new IO trials’ design to further improve survival
outcomes and minimize toxicity rates, new strategies are needed. We have identified five
main domains in the development of promising IO treatments that should be redefined for
more efficient results and accelerated approvals.
First, there is a crucial need for a biomarker-driven selection of a patient population
for each of the new IO agents. Second, the evaluation of efficacy, toxicity and comparisons
with current treatments should be based on surrogate endpoints and response criteria for
those specific IO agents and not just inferred from conventional drugs. Monitoring long
term-outcome seems to be mandatory as IO agent efficacy and toxicity may have long-term
effects [27]. Finally, changing the current scenario of IO clinical trial-design with more
collaborative approaches that facilitate the assessment of multiple diseases and drugs on a
biomarker basis seems crucial [28].
In this manuscript, we will analyze each of those points and suggest some potential
improvements in the field.
2. Challenges and Opportunities in IO Drugs Development
A summary of the main critical aspects in IO drug development and strategies for
their optimization is illustrated in Figures 1 and 2, respectively.
Figure 1. The major drawbacks found in immune-oncology trials designs to date. Abbreviations: IO:
immuno-oncology, RECIST: response evaluation criteria in solid tumors, iRECIST: immune response
evaluation criteria in solid tumors.
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Figure 2. Proposed strategies to optimize the clinical trial design for new immuno-oncology agents.
Abbreviations: RECIST: response evaluation criteria in solid tumors, iRECIST: immune response
evaluation criteria in solid tumors.
2.1. Response Criteria
From the beginning of the “IO era,” researchers realized that the standard response
evaluation criteria in solid tumors, namely RECIST alone, would not be suitable for im-
munotherapy due to the indirect effect caused by the participation of inflammatory cells
and their interactions [29]. RECIST relies on the early suppression of tumor growth
by chemotherapy and may consequently underestimate the benefit of immunotherapy.
The immune RECIST (iRECIST) and other immune-specific related response criteria
were developed to evaluate the heterogeneity of responsiveness in patients receiving
immunotherapy [30]. Although iRECIST takes into account pseudoprogressions or hyper-
progressions, which are observed exclusively with IO agents, demonstration of actual
response to treatment may not be distinguishable from such patterns for another several
months. This particular timeline may have caused many clinicians to have considered
patients as no treatment response and/or stable when the patient may have conversely ob-
tained benefit from treatment since iRECIST still recommends that assessment of response
durability may occur between 4 and 8 weeks [31].
The use of iRECIST for evaluation of response has mainly been used for studies
evaluating the efficacy of immunotherapeutic agents only. It becomes rather complex
when the primary objectives of trials are to perform head-to-head comparisons with non-
immunotherapeutic agents or combinations with other cytotoxic or molecular targeted
treatments. On the other hand, particular responses observed in patients undergoing
immunotherapy treatments are not well captured by iRECIST, such as dissociated responses
with some lesions growing, some shrinking or the slow progressions, features linked
with clinical benefit. In those cases, classic RECIST could still remain as a meaningful
method of evaluation [32]. In addition, most IO clinical trials that compare immunotherapy
with other cytotoxic antitumor agents are designed around the evaluation of response on
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superiority, inferiority or equivalence [33]. These comparisons may not be appropriate
when assessing two mechanistically different treatments, in which case integrative clinical
benefit and long-term outcome should be taken into consideration. Although the American
Society of Clinical Oncology-Society for Immunotherapy of Cancer (ASCO-SITC) has
recently recommended reporting responses according to both the conventional RECIST
and iRECIST criteria in parallel [34], this approach is still suboptimal as their evaluation is
done independently. Harmonizing and integrating both measurement methods into an
adequate tool rather than just separately considering both criteria is urgently warranted
for more precise measurements of actual responses.
It is worth noting that some methods beyond image evaluation have also shown
promising results for the assessment of response in IO. Some biomarkers assessed in periph-
eral blood such as interleukin 8 (IL-8), tumor circulating DNA (cDNA) or CD8+ memory
effector cytotoxic T cells have recently shown to assist in tracking immune response in
different tumors like NSCLC cancer and melanoma [35–37]. Given the strong correla-
tion between detected changes on those biomarkers with subsequent clinical responses,
biological assays exploring changes in their expression levels could lead to promising
results. Based on that, decisions could be made on the basis of patient-specific immuno-
logical tracking biomarkers. Moreover, the pathological assessment of lymphocytes and
immune infiltrating cells in tumor biopsies during treatment could also be considered as
a useful monitoring tool of clinical response in clinical trials and help to gain a deeper
understanding of the changes in tumor characteristics under immunotherapy. However,
the application of on-treatment biopsies in clinical practice remains unclear and should be
further investigated and refined as it could be considered invasive [38].
In summary, combining an integrative image tool with response markers such as
liquid biopsies could become better tailoring of response evaluation in the future of IO.
2.2. Long-Term Efficacy Endpoints and Surrogates
Drug approval is generally based on safety and efficacy assessed by clinically rel-
evant endpoints in phase 3 randomized trials. Overall, survival (OS) is considered to
be the gold standard as it reflects the ultimate survival benefit from cytotoxic and other
targeted therapy regimens, and there are minimal measurement errors in OS. Meanwhile,
progression-free survival (PFS) and objective response rate (ORR) are used as surrogate end-
points in cancer; these measurements provide inferred conclusions from clinical trials and
facilitate accelerated approval of new drugs that fill an unmet clinical need [39,40]. Other
emerging biological endpoint, such as changes in Ki67 level after short-term treatment with
endocrine therapy in BC, has been validated as a surrogate of long-term benefit [41] and
are increasingly becoming used as primary endpoints in clinical trials. Surrogate endpoints
for the assessment of IO agents’ efficacy have primarily been adopted for cytotoxic and
molecular targeted drugs; questions remain whether they are suitable to determine benefit
from immunotherapy. In particular, there are increased doubts concerning the use of
short-term benefit endpoints such as PFS or ORR as primary endpoints in most clinical
trials of new IO agents [7,42,43].
A recent meta-analysis of 60 published immunotherapy randomized clinical trials
suggested that ORR could be a meager surrogate of response to evaluate the efficacy of IO,
and the use of PFS as a surrogate of OS is still indeterminate [44]. Another meta-analysis
of 12 randomized clinical trials did not find a significant positive correlation between the
OS and PFS hazard estimates, suggesting that PFS assessment is not sufficient to capture
the benefit of PD-1-inhibitors in patients with solid tumors [42]. This is not surprising as
the unique mechanism of immunotherapy’s impact on tumors shows different patterns
of response and progression from other conventional agents [45]. Emerging biological
endpoints such as changes in Ki67 level are mainly driven by the antiproliferative effect of
certain drugs; however, its use in trials evaluating the combination of IO agents with cyto-
toxic and targeted drugs should be further explored. Recent studies have also shown that
endpoints taking into account a component of the duration of response such as milestone
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survival or durable response rate may better capture the delayed and persistent responses
derived from IO agents and should be further studied [46]. For instance, milestone survival
is the survival probability at a given time point, defined a priori as two years, and durable
response rate can be measured as a continuous response, such as complete or partial objec-
tive responses, beginning within 12 months of treatment and lasting ≥6 months [47]. The
advantages of such types of integrative endpoints are that they take into account particular
behaviors seen exclusively in IO and allow the use of predefined cutoff time intervals
that lead to the rapid characterization of survival probability and inference to long-term
survival data.
To date, overall survival still remains the gold standard for the evaluation of clinical
efficacy of IO agents in late-phase clinical trials, new biomarker-driven surrogate end-
points that capture the mechanisms of action in early phases of immunotherapy drugs
development should be explored.
2.3. Biomarkers of Response
Despite the rapid advance and reduced cost of high-throughput sequencing technolo-
gies, most current trials in oncology have limited use of biomarker-based selection and
stratification strategies in their designs. However, studies in IO treatments tested in unse-
lected populations are generally negative [48,49]. The lack of new and robust predictive
markers is particularly concerning for the selection of the most appropriate subpopulations
in relative “colder tumors” such as BC, in which most patients will not benefit from those
new IO agents.
In recent years more attention has been paid to the identification of predictive biomark-
ers of the efficacy of IO drugs to identify patients who benefit from those agents. Most ap-
proved immunotherapeutic treatments show efficacy only in selected populations, mainly
based on the immunohistochemical (IHC) levels of PD-L1 checkpoint target leading to
PD-L1 being the compulsory companion diagnostic assay for the administration of many
checkpoint inhibitors in oncology. Many efforts are currently focusing on the reproducibil-
ity and standardization of laboratory protocols for the IHC assessment. However, the
evaluation of single IHC biomarkers does not completely explain the heterogeneity of
tumors, and their use seems to be suboptimal in the “genetics and omics era”. In particular,
multiplex diagnostic assays would be better, especially when testing IO agents beyond
immune checkpoint inhibitors [14–19].
Emerging predictive biomarkers as defined by both the host and tumor factors are
promising measurement for a clinical response; the use of these measurements are still in
infancy stage due to a lack of standardization and harmonization of reporting methods [50].
Tumor mutational burden, microsatellite instability, and tumor neoantigen loads are some
examples. Mutational burden and high microsatellite instability assessment based on
mutations in mismatch repair genes have been associated with better response to im-
munotherapy, especially to anti-programmed cell death protein 1 (anti-PD1) agents [51,52].
Next-generation sequencing has led to a more accurate method of quantification, but it is
still difficult to achieve a homogenization on their quantification. Thus, the implementation
and standardization of robust bioinformatics methodologies and analytical techniques
across laboratories are necessary [53]. Additional exploration to identify the type of muta-
tions is much needed for generating the most relevant neoantigen for recognition by the T
cells. Other challenges are that these emerging predictive biomarkers assays for IO agents
are usually expensive, technically demanding and not widely available.
Multi-plex and multi-omics based biomarkers indicating higher tumor immune toler-
ance such as immune-related genes and signatures have thrown some light on the field
of predictive biomarkers in IO [20,54]. Some studies have shown that high expression of
some particular gene expression signatures is associated with response to PD-L1 inhibitors
regardless of their PD-L1 status in NSCLC and melanoma [55]. Other signatures, including
some targetable immune checkpoint components such as indoleamine 2,3-dioxygenase
(IDO1), lymphocyte-activation gene 3 (LAG-3), or interferon-gamma (IFNγ) genes can pre-
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dict benefit from immunotherapy in “colder tumors” such as luminal B BC patients [56,57].
Recent studies have also demonstrated that exhausted CD8+. T cell signatures can predict
immunotherapy response in ER-positive BC [58]. These signatures are yet to be validated
in clinical trials.
Identification of robust pharmacodynamic biomarkers of IO response remains a
challenge [59], and it is likely that combinations of two or more biomarkers to capture
immune status more accurately will be needed [20].
2.4. Definition of Toxicity and Treatment Dosage
Immunotherapies have the potential to induce toxicity profiles distinct from those
from other cancer treatments. Immune-related adverse events are often underdiagnosed,
as patients can remain asymptomatic for long periods of time [10,12]. In addition, toxicity
is mostly inflammatory-related, and assumptions from cytotoxic or molecular targeted
treatments are not appropriate for IO agents. In particular, precise considerations must be
taken during their development [60] as they do not fit the dose–response/dose-toxicity
relationships seen with cytotoxic therapies.
In contrast to what usually happens with cytotoxic drugs, an increase in the dosage
above the biologically optimal does not always correlate with an increase in efficacy or
toxicity in IO [7]. Due to the lack of reliable toxicity endpoints to establish optimal dosages
in immunotherapeutic trials, some FDA approvals on immune-checkpoints inhibitors
have been based on varying dosages and schedules across different tumor types. This
has resulted in some confusion on the clinical implication and implementation for future
trial designs [32]. The best approach to define the optimal administration dosages and
schedules with the highest efficacy is still open-ended, and deficient toxicity profiles may
have unfortunately an impinged on the results from several clinical trials assessing efficacy
with IO agents [61].
The optimal design of early phase clinical trials should aim to evaluate doses and
schedules at the minimal doses that are biologically active. Based on the distinct be-
havior of IO agents, flat dosing administration instead of weight-based dosing may be
a better approach facilitating smoother administration and avoiding drug waste [62,63].
Long-term follow-up of IO related adverse events is encouraged in trial designs evalu-
ating new-IO agents. Consensus guidelines for recognizing each of the adverse events
under immunotherapy and specific management of these reported events should also
be incorporated.
Aforementioned, defining doses and schemes of IO agents seem relatively more
complicated than with cytotoxic drugs. New approaches in trial designs, including the
homogenization of the optimal dosages that will be carried over later phases of drug
development, are urgently needed. Finally, the incorporation of additional endpoints
especially validated for IO agents in early phases of trials for dose selection to improve
efficacy and reduced toxicity, are also warranted.
2.5. The Trial Design Itself
Due to the particular impact on tumor biology by IO treatments, conventional phase 3
clinical trial designs to demonstrate the effects of an experimental therapy compared to
standard of care are unlikely to provide definitive answers on the efficacy of IO within
reasonable time and cost. The anti IDO1 epacadostat, which was evaluated in a late-
phase trial in melanoma, is an example of such a conundrum [6]. This phase III trial
ECHO-301/KEYNOTE 252 trial was designed to assess the efficacy of IDO1 inhibition in
combination with pembrolizumab, but there were several problems associated with the
trial, including the use of endpoints such as PFS and ORR and no pre-planned translational
studies to study the tumor biology leading no collection of biological samples that could
be studied further to explain the unexpected clinical results [62,63]. This study has posed
that translational studies are important elements to be incorporated in the trial design
whenever possible.
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Furthermore, the field of IO is currently overcrowded with several drugs competing
for the same therapeutic space. Advancements in “precision oncology” urge therapy
selection based on tumor molecular characteristics. The conventional trial designs, lack of
pairing tumor characteristics with therapeutic targets, are not adequate to investigate the
broad-spectrum of genetic makeup in tumors that may benefit from different IO agents
and targeted therapies. The incorporation of “master protocols” in collaborative clinical
study designs can allow multiple disease assessments and multiple strategies at a time.
Some “modern” strategies also include several trial designs that enable more personalized
and adaptative assessment of new drugs, such as platform trials, which can be multi-arm,
multi-stage adaptive studies, pairing targeted therapy with molecular characterization of
tumors [64]. Other simpler approaches include umbrella trials, which evaluate multiple
targeted therapies for a single disease as defined by specific molecular characteristic
subgroups, and basket trials, which use biomarkers for molecular screening and allocation
of patients into different trials according to their molecular biology [65,66].
These new approaches in trial designs alleviate the field of IO by optimizing resources
and improving the efficiency of the broad amount of emergent clinical trials. However,
those new designs require considerable effort, cost and multidisciplinary collaboration.
Regulatory approvals and standardization of their use warrant further exploration. The
question remains whether a systematic implementation of renewed IO drug designs and
translational studies should be encouraged to avoid superfluous numbers of clinical trials.
3. Conclusions
The current clinical development of IO agents has both strengths and weaknesses that
provide us with challenges and opportunities for improvement. Given the rapid growth
in the IO field, only a greater level of understanding of the underlying mechanisms of
resistance, tumor heterogeneity and host and tumor microenvironment can shed light on
IO for patient selection through robust biomarkers testing. The silhouette in clinical trial
design and response evaluation criteria of IO should be redefined with new approaches
like amalgamating integrative tools with response biomarkers such as the use of liquid
biopsies. Applying innovative but appropriate clinical trial designs, incorporating multiple
robust biomarkers assays of response and surrogate endpoints, will lead to the best possible
development and accelerated approvals of new IO agents that are here to stay. Finally, the
precise definition of adverse events following long-term evaluation and dosage definition
is also needed for successful results. With advances in molecular sequencing technologies
and development in machine-learning methods, biomarker-driven strategies to assist the
selection of patients for future trials with immunotherapy will soon be a reality.
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